Oral and injectable antiquaguane in the prevention of thromboembolic events

Phase 2

• Conditions: Condition 1: Thrombosis. Condition 2: Pulmonary embolism.; Acute embolism and thrombosis of deep veins of lower extremity; Pulmonary embolism; I82.4

• Registration Number: IRCT20231026059867N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

People who have undergone surgery for gynecological cancers
Candidate to receive oral or injectable anticoagulants

Exclusion Criteria

Lack of consent to continue participating in the study
History of thromboembolic events

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Venous thrombosis. Timepoint: 2 and 6 and 12 weeks after starting treatment. Method of measurement: Physical examination and history taking.;Pulmonary embolism. Timepoint: 2 and 6 and 12 weeks after starting treatment. Method of measurement: Physical examination and history taking.